Anabel Soldano1, Huili Yao1, Achala N D Punchi Hewage2, Kevin Meraz3, Joel K Annor-Gyamfi3, Richard A Bunce3, Kevin P Battaile4, Scott Lovell5, Mario Rivera1. 1. Department of Chemistry, Louisiana State University, 232 Choppin Hall, Baton Rouge, Louisiana 70803, United States. 2. Department of Chemistry, University of Kansas, 2030 Becker Drive, Lawrence, Kansas 66047, United States. 3. Department of Chemistry, Oklahoma State University, Stillwater, Oklahoma 74078, United States. 4. NYX, New York Structural Biology Center, Upton, New York 11973, United States. 5. Protein Structure Laboratory, University of Kansas, 2034 Becker Drive, Lawrence, Kansas 66047, United States.
Abstract
Bacteria depend on a well-regulated iron homeostasis to survive adverse environments. A key component of the iron homeostasis machinery is the compartmentalization of Fe3+ in bacterioferritin and its subsequent mobilization as Fe2+ to satisfy metabolic requirements. In Pseudomonas aeruginosa Fe3+ is compartmentalized in bacterioferritin (BfrB), and its mobilization to the cytosol requires binding of a ferredoxin (Bfd) to reduce the stored Fe3+ and release the soluble Fe2+. Blocking the BfrB-Bfd complex in P. aeruginosa by deletion of the bfd gene triggers an irreversible accumulation of Fe3+ in BfrB, concomitant cytosolic iron deficiency and significant impairment of biofilm development. Herein we report that small molecules developed to bind BfrB at the Bfd binding site block the BfrB-Bfd complex, inhibit the mobilization of iron from BfrB in P. aeruginosa cells, elicit a bacteriostatic effect on planktonic cells, and are bactericidal to cells embedded in mature biofilms.
Bacteria depend on a well-regulated iron homeostasis to survive adverse environments. A key component of the iron homeostasis machinery is the compartmentalization of Fe3+ in bacterioferritin and its subsequent mobilization as Fe2+ to satisfy metabolic requirements. In Pseudomonas aeruginosaFe3+ is compartmentalized in bacterioferritin (BfrB), and its mobilization to the cytosol requires binding of a ferredoxin (Bfd) to reduce the stored Fe3+ and release the soluble Fe2+. Blocking the BfrB-Bfd complex in P. aeruginosa by deletion of the bfd gene triggers an irreversible accumulation of Fe3+ in BfrB, concomitant cytosolic iron deficiency and significant impairment of biofilm development. Herein we report that small molecules developed to bind BfrB at the Bfd binding site block the BfrB-Bfd complex, inhibit the mobilization of iron from BfrB in P. aeruginosa cells, elicit a bacteriostatic effect on planktonic cells, and are bactericidal to cells embedded in mature biofilms.
Entities:
Keywords:
Pseudomonas aeruginosa; bacterioferritin; biofilm; iron homeostasis; iron metabolism
Antimicrobial
resistant bacteria
are a major threat to public health. The World Health Organization
(WHO) has released a priority list of pathogens for which antibiotics
are urgently needed.[1] Carbapenem-resistant Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobactereceae are at the top of the WHO
priority list because of their resistance to multiple drug classes
and associated mortality. P. aeruginosa, one
of the leading Gram-negative pathogens associated with nosocomial
infections has a propensity to form biofilms, which are populations
of bacteria living in organized structures embedded in a self-produced
matrix of DNA, proteins, and polysaccharides.[2−4] Although the
preference of bacteria for a biofilm lifestyle was reported almost
80 years ago, the ubiquitous involvement of biofilms in chronic infection
has been recognized more recently.[5,6] Biofilm-related
diseases are typically persistent infections that develop relatively
slowly, are rarely resolved by the immune system and respond poorly
or transiently to antibiotics.[7] Some examples
are chronic wound infection, chronic otitis media, osteomyelitis,
recurrent urinary tract infection, endocarditis, and cystic fibrosis-associated
infections which can accelerate lung function decay in cystic fibrosispatients.[8,9] Biofilms can also colonize indwelling catheters,
stents, orthopedic implants, endotracheal tubes and urinary catheters,[10−12] and are ubiquitous in burn wounds and in chronic nonhealing wounds,
including diabetic foot ulcers, pressure ulcers and venous leg ulcers.[13,14] Bacteria in biofilms are thought to be phenotypically and physiologically
different from nonadhered, free living (planktonic) cells.[15] Susceptibility tests have shown that the minimal
inhibitory concentration (MIC) and minimal bactericidal concentration
(MBC) of antibiotics that are required to challenge bacteria in mature
biofilms can be 10- to 100-fold higher than those required for planktonic
bacteria.[16−18] This intrinsic tolerance to antibiotics, which is
thought to be an important reason for the persistence of biofilm infections,[6,10] generates an urgent need to discover novel antibiotics and to validate
new targets for combatting the threat posed by multidrug resistant
organisms and overcoming the limitations of conventional antibiotics
to treat chronic (biofilm) infections.[19−21]Iron is an essential
element in biology, and a required cofactor
for many enzymes that participate in important physiological processes,
such as respiration, DNA synthesis, and amino acid synthesis.[22] Iron homeostasis in bacteria offers a significant
vulnerability because invading pathogens must obtain essential iron
from the host, but host-defenses maintain the concentration of free
iron at a vanishingly low level (∼10–18 M).[22] Pathogens have evolved mechanisms to “steal”
iron from their host, but these depend strongly on well-regulated
iron homeostasis.[23,24] Consequently, we have proposed
iron storage proteins as a new and specific target for dysregulating
bacterial iron homeostasis.[23,25,26] Our work has showed that although two ferritin-like molecules coexist
in P. aeruginosa, bacterioferritin B (BfrB)
is the main iron storage protein.[23,27] Bacterioferritin,
which only exists in bacteria, is a spherical protein that can store
up to ∼3000 Fe3+ ions in its interior cavity (∼80
Å diameter). Bacterioferritin is unique in that it binds 12 heme
groups buried under the external protein surface, which allows the
heme propionates to protrude into the interior cavity (Figure A).[28,29] We demonstrated that mobilization of iron from BfrB requires specific
interactions with the bacterioferritin-associated ferredoxin (Bfd).[30,31] The structure of Bfd revealed a new class of [2Fe-2S] protein[32] and the crystal structure of the BfrB-Bfd complex
showed that up to 12 Bfd molecules can bind at identical sites on
the BfrB surface, at the interface of subunit dimers, above a heme
molecule (Figure B).[30] The heme mediates electron transfer between
the [2Fe-2S] cluster of Bfd and the Fe3+ mineral stored
in the BfrB cavity, enabling mobilization of Fe2+ to the
cytosol.[28,30] The Bfd binding sites on BfrB are equivalent
and independent, where Bfd binds with a Kd of 3 μM.[33]
Figure 1
(A) BfrB from Pseudomonas aeruginosa (PDB ID 3is7) is a spherical
and hollow protein assembly which can store up to 3000 Fe3+ in the interior cavity. A heme molecule (cyan) binds between two
subunits, where it is buried under the exterior surface with the heme
propionates exposed to the interior cavity. (B) Structure of the BfrB-Bfd
complex (PDB ID 4E6K) where a Bfd molecule (blue) binds at the interface of two BfrB
subunits (green), above a heme molecule (cyan). Electron transfer
from the [2Fe-2S] cluster in Bfd to the Fe3+ in the interior
of BfrB is mediated by the heme. The resultant Fe2+ exits
the BfrB molecule for incorporation in bacterial metabolism.
(A) BfrB from Pseudomonas aeruginosa (PDB ID 3is7) is a spherical
and hollow protein assembly which can store up to 3000 Fe3+ in the interior cavity. A heme molecule (cyan) binds between two
subunits, where it is buried under the exterior surface with the heme
propionates exposed to the interior cavity. (B) Structure of the BfrB-Bfd
complex (PDB ID 4E6K) where a Bfd molecule (blue) binds at the interface of two BfrB
subunits (green), above a heme molecule (cyan). Electron transfer
from the [2Fe-2S] cluster in Bfd to the Fe3+ in the interior
of BfrB is mediated by the heme. The resultant Fe2+ exits
the BfrB molecule for incorporation in bacterial metabolism.Studies conducted with P. aeruginosa PAO1
and a mutant where the bfd gene has been deleted
(Δbfd) showed that in the absence of Bfdiron
is irreversibly accumulated in BfrB, thus demonstrating that Bfd is
required to mobilize iron stored in bacterioferritin. These studies
also showed that the irreversible accumulation of iron in BfrB is
accompanied by depletion of free iron in the cytosol.[23] Given that P. aeruginosa requires
sufficient environmental and intracellular iron reserves to establish
mature biofilms,[34−37] we reasoned that the iron deficiency that ensues in the cytosol
of the Δbfd cells might adversely affect biofilm
formation. Studies conducted to pursue this idea showed that the Δbfd cells form poorly developed biofilms and that the biofilm-embedded
cells experience cytosolic iron deficiency, even in iron-sufficient
culture media.[26] These findings, which
underscored the inhibition of the BfrB-Bfd complex as a viable target
to dysregulate iron homeostasis and possibly develop novel antimicrobial
tools, encouraged us to conduct a fragment-based structure-guided
campaign to discover inhibitors of the BfrB-Bfd complex. These efforts
allowed us to identify derivatives of 4-aminoisoindoline-1,3-dione
which bind BfrB selectively at the Bfd binding site,[25] block the BfrB-Bfd complex in the P. aeruginosa cytosol, and inhibit the mobilization of bacterioferritin-stored
iron.[25] Challenging planktonic cultures
of P. aeruginosa with the 4-aminoisoindoline-1,3-dione
analogues elicited a dose-dependent growth inhibition phenotype, thus
providing proof of concept for the usefulness of small molecules designed
to inhibit the BfrB-Bfd complex as probes to dysregulate iron homeostasis
and weaken bacterial cells.[25] Herein we
report on improvements made to the 4-aminoisoindoline-1,3-dione derivatives
which increase the binding affinity for BfrB and the bacteriostatic
activity against planktonic P. aeruginosa cells.
Surprisingly, the 4-aminoisoindoline-1,3-dione derivatives are bactericidal
to P. aeruginosa cells embedded in mature biofilms.
The killing effect of the BfrB-Bfd complex inhibitors on biofilm cells,
which are normally recalcitrant to several classes of commercial antibiotics,
has uncovered a rare weakness that may be exploited to control biofilms.
Results
and Discussion
Synthesis of 4-Aminoisoindoline-1,3-dione
Derivatives
Solving the X-ray structure of the BfrB-Bfd complex[30] and identifying the hot-spot residues participating
at
the protein–protein interface[33] provided
a unique molecular platform to study the mechanisms that enable mobilization
of bacterioferritin-stored iron.[28] The
structural information also enabled a fragment based structure-guided
strategy to discover inhibitors of the BfrB-Bfd complex. Fragment
screening followed by efforts to cocrystallize the fragment hits with
BfrB produced the X-ray crystal structure of BfrB in complex with
4-aminoisoindoline-1,3-dione (8) binding at the Bfd-binding
site.[25] The cocrystal structure informed
a strategy for fragment growth that produced a series of 4-(benzylamino)-
and 4-((3-phenylpropyl)amino)isoindoline-1,3-dione analogues represented
by 11 and 16 (Table ), which are derivatives of 8 with −(CH2)– and −(CH2)3– linkers, respectively.[25,38] These analogues were shown to selectively bind BfrB at the Bfd binding
site and to elicit a growth defect in P. aeruginosa planktonic cell cultures.[25] To increase
the binding affinity of 11 and 16 for BfrB
we looked for information in the available structural data. For example,
the crystal structures of 11 and 16 bound
to BfrB show clear electron density defining the aminoisoindoline-1,3-dione
(phthalimide) moieties. The hydroxy-substituted phenyl rings, however,
are less well-defined by electron density, suggesting that conformational
disorder of the phenyl ring in the cleft formed by L68 and E81 may
influence the stability of the complex.[25] In an attempt to lower disorder of the phenyl ring, we prepared
a set of 4-aminoisoindoline-1,3-dione derivatives bearing a relatively
bulky halogen atom in the phenyl ring (Table ). A schematic summary of the representative
syntheses for compounds with −(CH2)– or −(CH2)3– linkers is shown in Figure . For example, compound KM-5-25 was prepared from 5-chlorosalicylaldehyde by reductive
amination with 8 in N,N-dimethylformamide (DMF) solution using sodium triacetoxyborohydride
as the reducing agent. Compound KM-5-66 was prepared
from 3-chloro-5-hydroxybenzaldehyde; the phenol was protected with tert-butyldimethylsilyl chloride (TBSCl) and the side chain
elongated by Horner–Wadsworth–Emmons reaction to the
α, β-unsaturated ester. Subsequent catalytic reduction
of the side chain double bond followed by diisobutylaluminum hydride
(DIBAL-H) reduction of the ester under carefully controlled temperature
conditions furnished the requisite 3-arylpropionaldehyde. This aldehyde
was then linked by reductive amination to 8 as above
and deprotected with tetrabutylammonium fluoride (TBAF) in THF. Additional
details are presented in the Supporting Information.
Table 1
Structure, Binding Affinity, and IC50 of 4-Aminoisoindoline-1,3-dione Derivatives
Not determined
because of low solubility
(<30 μM) in PBS buffer.
Figure 2
Schematic summary of the synthetic process to prepare 4-(benzylamino)isoindoline
(i.e., KM-5-25) and 4-((3-phenylpropyl)amino)- (i.e., KM-5-66) derivatives of 4-aminoisoindoline-1,3-dione.
Schematic summary of the synthetic process to prepare 4-(benzylamino)isoindoline
(i.e., KM-5-25) and 4-((3-phenylpropyl)amino)- (i.e., KM-5-66) derivatives of 4-aminoisoindoline-1,3-dione.Not determined
because of low solubility
(<30 μM) in PBS buffer.
4-Aminoisoindoline-1,3-dione Derivatives Elicit a Bacteriostatic
Effect in Planktonic P. aeruginosa Cultures
The relative strength of the association between the new analogues
and BfrB was evaluated measuring the dissociation constant Kd (Table , Figure S1). The results show
that installing a halogen atom in the phenyl ring improves the binding
affinity of the derivatives relative to the previously reported analogues 11 and 16. The Kd values of halogen containing compounds with a −(CH2)– linker are on average ∼2-fold lower when compared
to the Kd exhibited by 11, and the Kd values of halogen-bearing
analogues with a −(CH2)3– linker
are on average ∼5-fold lower than the Kd measured for analogue 16. The relative efficacy
of the analogues to inhibit P. aeruginosa planktonic
growth was evaluated by measuring the half maximal inhibitory concentration
(IC50). Inspection of the data in Table shows that all of the halogenated compounds
are more active than analogues 11 and 16; the activity of KM-5-29 and KM-5-54 could
not be evaluated because the relatively low aqueous solubility of
these compounds prevented measurement of their IC50 values.Although the compounds synthesized so far do not include all possible
substitution isomers, some insights of the governing structure activity
relationships have begun to emerge (Table ): (i) Among the compounds
with a −(CH2)– linker, the data reveal that
when the hydroxyl group is at position 2 relative to the linker (KM-5-29, JAG-5-7, KM-5-25, and KM-5-30) a bulkier Cl atom at position 5 (KM-5-25) imparts ∼2-fold higher binding affinity for BfrB than a
smaller F atom at the same position (JAG-5-7). In line
with the nearly 2-fold lower Kd, the IC50 of KM-5-25 is ∼2-fold lower than that
of JAG-5-7. In comparison, a Cl atom at position 3 (KM-5-30) imparts a Kd similar
that of KM-5-25, but an IC50 ∼ 2.5-fold
larger, suggesting that KM-5-30 is less efficient at
penetrating or accumulating in P. aeruginosa cells. Installing a Cl atom at position 6 (KM-5-29)
renders the compound poorly soluble in aqueous solution. It is also
interesting to compare the two analogues with a hydroxyl group at
position 3. The presence of a Cl atom at position 5, KM-5-50, lowers the Kd by a factor of 2 relative
to BN-XIV-53 and improves the activity vs planktonic
cells significantly. (ii) Examining the compound
series with a −(CH2)3– linker
shows that when the hydroxyl group is at position 3, a Cl atom at
position 5 (KM-5-66) decreases the Kd ∼ 4-fold and the IC50 ∼ 3-fold
relative to compound 16. In comparison, the presence
of a second hydroxyl group at position 5 (KM-5-57) increases
the Kd ∼ 1.7-fold relative to 16 and renders the compound inactive. Given that the Kd measured for KM-5-57 is similar
or lower than Kd values measured for other
active compounds in Table , the immeasurable activity of KM-5-57 suggests
that it cannot penetrate or accumulate in P. aeruginosa cells. Finally, comparison of compounds where the hydroxyl group
is at position 2 (KM-5-28, JAG-5-6, and KM-5-54) also shows that a halogen at position 5 improves
binding affinity. A bulkier Cl atom at position 5 increases the binding
affinity of KM-5-54 2-fold relative to the compound with
a F at the same position (JAG-5-6). Comparing the IC50 values corresponding to KM-5-28 and JAG-5-6 reveals that the ∼3-fold lower Kd caused by installing a F atom at position 5 is accompanied by ∼2-fold
decrease in the IC50. Attempts to determine whether the
lower Kd obtained when a Cl atom at position
5 would bring an additional decrease in the IC50 were stymied
by the poor water solubility of KM-5-54.The structure–activity
relationships (SAR) information available
thus far indicates that a halogen in the aryl ring of the 4-aminoisoindoline-1,3-dione
derivatives invariably improves binding affinity for BfrB. In compounds
with a −(CH2)– linker, when the hydroxyl
group is at position 2, a Cl atom at position 5 imparts favorable
properties, a Cl atom at position 3 renders the compound poorly active
vs P. aeruginosa, despite relatively favorable Kd, and a Cl atom at position 6 imparts poor
aqueous solubility. The preparation of compounds with a −(CH2)3– linker is more elaborate and accessibility
to suitable starting materials at reasonable prices is also more limited.
The information available thus far indicates that although a Cl at
position 5 is favorable whether the hydroxyl group is at position
2 or 3, poor aqueous solubility impairs the potential biological activity
when the hydroxyl is at position 2 (KM-5-54), despite
having the most favorable Kd of all compounds
in Table . Attempts
to increase aqueous solubility by installing a hydroxyl group at position
5 succeeded in increasing solubility but rendered a compound (KM-5-57) with lower affinity for BfrB and inactive against P. aeruginosa cells. As new compounds become available,
similar evaluation of binding affinity and activity against bacterial
cells will continue to shed light on the structural requirements that
simultaneously enhance target affinity in vitro and activity against P. aeruginosa cells. For the purposes of the studies
described below, we chose to work with compounds KM-5-25, the most active of the analogues containing a −(CH2)– linker, and KM-5-66, the most active of the
analogues harboring a −(CH2)3–
linker.
Structures of Representative 4-Aminoisoindoline-1,3-dione Derivatives
Bound to BfrB
To gain additional evidence for the selectivity
of the 4-aminoisoindoline-1,3-dione derivatives for the Bfd binding
site on BfrB, we carried out ligand soaking experiments aimed at obtaining
cocrystals of compound bound to the bacterioferritin. These experiments
resulted in the X-ray crystal structures of KM-5-28, KM-5-66, KM-5-50, and JAG-5-7 bound
to BfrB; refinement statistics are summarized in Table S1. In all four structures the 4-aminoisoindoline-1,3-dione
(phthalimide) moiety binds at the Bfd binding site with a nearly identical
pose, forming hydrogen bonding interactions to the O atom of P69 and
the backbone N atoms of L71 and N70 (Figures A,B, 4A,B, and S2). This binding mode, which is nearly identical
with that observed in the previously reported structures of 11, 16, and several other analogues,[25] provides strong evidence for the selectivity
of the 4-aminoisoindoline-1,3-dione derivatives for the Bfd site on
BfrB. The linkers and phenyl rings also bind BfrB at the Bfd binding
site, where they fit in a cleft formed by the side chains of L68 and
E81. As will be discussed below, the details of binding are particular
to whether the compound harbors a −(CH2)–
or a −(CH2)3– linker and to the
substitution pattern on the ring.
Figure 3
Binding of KM-5-66 to the
Bfd binding site on BfrB.
Subunits A and B of a BfrB subunit dimer are rendered as surface and
colored in gray and green, respectively. (A) Fo – Fc omit map contoured
at 3σ (coral mesh) from KM-5-66 bound on BfrB.
(B) Hydrogen bonding interactions (dashed lines) between KM-5-66 and BfrB. (C) View along the 3-hydroxyl-5-chloro phenyl ring plane
of KM-5-66 (coral) depicted as a surface rendering along
with residues surrounding the phenyl ring. (D) View depicting the
3-hydroxyl-5-chloro phenyl ring position relative to residues M31
and W35; pertinent distances are indicated by solid lines. The Cl
atom of KM-5-66 is depicted in green.
Figure 4
Binding of JAG-5-7 to the Bfd binding site on BfrB.
(A,B) Fo – Fc omit map contoured at 3σ (coral mesh) from JAG-5-7 bound at the Bfd binding site in one of the BfrB subunit dimers,
and hydrogen bonding interactions (dashed lines). The 2-hydroxyl-5-fluoro
phenyl ring is observed in only one conformation at this binding site.
(C,D) View of a different binding site where the 2-hydroxyl-5-fluoro
phenyl ring is observed in two conformations; in one of the conformations
the hydroxyl group is hydrogen bonded to the carbonyl oxygen of G80.
The F atom of JAG-5-7 is depicted in green.
Binding of KM-5-66 to the
Bfd binding site on BfrB.
Subunits A and B of a BfrB subunit dimer are rendered as surface and
colored in gray and green, respectively. (A) Fo – Fc omit map contoured
at 3σ (coral mesh) from KM-5-66 bound on BfrB.
(B) Hydrogen bonding interactions (dashed lines) between KM-5-66 and BfrB. (C) View along the 3-hydroxyl-5-chloro phenyl ring plane
of KM-5-66 (coral) depicted as a surface rendering along
with residues surrounding the phenyl ring. (D) View depicting the
3-hydroxyl-5-chloro phenyl ring position relative to residues M31
and W35; pertinent distances are indicated by solid lines. The Cl
atom of KM-5-66 is depicted in green.Binding of JAG-5-7 to the Bfd binding site on BfrB.
(A,B) Fo – Fc omit map contoured at 3σ (coral mesh) from JAG-5-7 bound at the Bfd binding site in one of the BfrB subunit dimers,
and hydrogen bonding interactions (dashed lines). The 2-hydroxyl-5-fluoro
phenyl ring is observed in only one conformation at this binding site.
(C,D) View of a different binding site where the 2-hydroxyl-5-fluoro
phenyl ring is observed in two conformations; in one of the conformations
the hydroxyl group is hydrogen bonded to the carbonyl oxygen of G80.
The F atom of JAG-5-7 is depicted in green.The structure of KM-5-66 (Figure ) shows the −(CH2)3– linker wedged at the “floor” of the
cleft formed by the side chains of L68 and E81 on BfrB (Figure A,B), where it engages in hydrophobic
packing with the several residues forming the cleft floor and with
the hydrophobic portion of the L68 and E81 side chains. The 3-hydroxyl-5-chloro
phenyl ring, which is nearly parallel with the cleft floor, enables
the 3-hydroxyl group to interact with the E81 carbonyl oxygen via
H-bonding, and the Cl atom to interact with the side chains of L63
and L68 (Figure A,B).
The phenyl ring, at its closest point, is also 3.60 Å from the
M31 CE atom, a favorable interaction that is also probable
to hinder rotation of the ring toward a perpendicular position relative
to the cleft floor (Figure C,D). It is also interesting to note that the 3-hydroxyl-5-chloro
phenyl ring is positioned to form a pseudo edge-to-face interaction
with the indole ring of W35; the phenyl ring, at its closest position,
is 3.77 Å from the indole ring CZ2 atom, the distance
between the centroids of the phenyl and the indole 6-member ring is
5.92 Å, and the angle between the planes of these rings is 67.4°,
suggesting a weak edge-to-face interaction.Despite significant
effort, we could not obtain good diffraction
data from BfrB crystals soaked in solutions containing KM-5-25. However, we were able to obtain the structure of the fluorinated
analogue JAG-5-7 (Figure ). Strong electron density consistent with JAG-5-7 was observed in 8 of the 12 subunits. The shorter −(CH2)– linker places the 2-hydroxyl-5-fluoro phenyl ring
well within the cleft formed by the side chains of L68 and E81, with
the ring nearly perpendicular to the cleft floor. The electron density
from the 2-hydroxyl-5-fluoro phenyl ring is consistent with the ring
experiencing one orientation in certain subunits (Figure A,B) and with the ring in two
conformations in other subunits (Figure C,D). In one of these orientations the hydroxyl
group forms a H-bond with the carbonyl oxygen of G80, whereas the
fluorine atom packs against the side chain of L68. The structure of KM-5-50 (Figure S2), also places
the 3-hydroxyl-5-chloro phenyl ring within the cleft formed by L68
and E81, in a similar nearly perpendicular conformation relative to
the cleft floor, except that no H-bonding was observed for the 3-hydroxyl
group.Taken together, the structures of the 4-aminoisonindoline-1,3-dione
derivatives reported here and those reported previously[25] provide important insights. The linkers and
the phenyl rings of all the compounds containing a −(CH2)3– linker adopt nearly identical binding
modes, with the phenyl rings oriented parallel to the cleft floor
(Figure S3) and positioned to engage the
6 member ring of the indole in W35. Superposing the structures of
analogue 16 and KM-5-66 (Figure S4A) shows that the phenyl ring in 16 is
notably pitched relative to the phenyl ring in KM-5-66 (the angle between the mean planes of both rings is 22.6°),
and the 3-hydroxyl group is not engaged in H-bonding interactions.
In comparison, the Cl atom at position 5 in KM-5-66 appears
to induce a nearly parallel orientation of the ring relative to the
cleft floor and a conformation that places the 3-hydroxyl within H-bonding
distance of the carbonyl oxygen of E81. Together, the H-bonding engagement
of the 3-hydroxyl group, the packing of the Cl atom with the side
chains of L63 and L68, and the more extensive packing of the phenyl
ring against the cleft floor residues are probably responsible for
the higher affinity of KM-5-66 for BfrB relative to 16. It is also interesting to note that in the structures
of all the compounds with a shorter −(CH2)–
linker the phenyl ring is nearly perpendicular to the cleft floor.
This is illustrated by superposing the structures of KM-5-66 and JAG-5-7 (Figure S4B),
which shows that the phenyl rings of both compounds adopt a nearly
perpendicular angle (74°) relative to one another. The structural
information currently available suggests that the shorter linker and
the relatively less efficient packing of the phenyl ring against the
hydrophobic portions of the L68 and E81 side chains may contribute
to the higher Kd values of these compounds
relative to those with a −(CH2)3–
linker.
Planktonic P. aeruginosa Cells Treated
with 4-Aminoisoindoline-1,3-dione Derivatives Overproduce Pyoverdine
Previous studies directed at evaluating the repercussions of blocking
the BfrB-Bfd complex in P. aeruginosa cells
relied on deleting the bfd gene (Δbfd). These investigations showed that blockade of the BfrB-Bfd complex
in planktonic Δbfd cells causes an irreversible
accumulation of iron in BfrB and iron deficiency in the cytosol. The
resultant phenotype is hyperproduction of pyoverdine relative to the
wild type cells.[23] Pyoverdine is a siderophore
produced by P. aeruginosa when the cells experience
iron limitation.[39] A similar pyoverdine
overproduction phenotype was observed when wild type P. aeruginosa cells were treated with small molecule inhibitors of the BfrB-Bfd
complex (11 and 16).[25] Therefore, to determine that compounds KM-5-25 and KM-5-66 inhibit iron mobilization from BfrB in
the P. aeruginosa cytosol, we investigated whether
cells treated with these compounds express the characteristic pyoverdine
hyperproduction phenotype. To this end, planktonic cells were cultured
in the presence of KM-5-25 (70 μM) or KM-5-66 (50 μM) for 27 h in M63 media and the content of the secreted
pyoverdine in the cell-free spent media was analyzed by measuring
the fluorescence intensity at 460 nm. Normalizing the intensity of
pyoverdine fluorescence to CFU/mL shows that as expected, cells treated
with KM-5-25 or KM-5-66 secrete ∼5-fold
more pyoverdine than the untreated control (Figure S5), an overproduction level similar to that observed with
the Δbfd mutant.[23] These observations indicate that both analogues bind BfrB in the P. aeruginosa cytosol, block the BfrB-Bfd interaction
and inhibit iron mobilization from BfrB, resulting in cytosolic iron
limitation that is manifested in a pyoverdine hyperproduction phenotype.
The cytosolic iron limitation caused by treating planktonic cultures
with KM-5-25 or KM-5-66 exerts a bacteriostatic
effect on the cells, as indicated by the IC50 values in Table . In stark contrast,
when the same compounds are used to treat P. aeruginosa biofilms, a bactericidal effect is observed. The results from these
experiments are discussed below.
4-Aminoisoindoline-1,3-dione
Derivatives Kill P. aeruginosa Cells in Mature
Biofilms
A characteristic of biofilms is
their high tolerance to antimicrobial agents. Tolerance is a physiological
condition which does not involve mutation and enables bacteria to
survive in the presence of antibiotics.[40−43] The persistent biofilm phenotype
is thought to arise from several factors, including restricted penetration
of antibiotic molecules due to interactions with components of the
biofilm matrix, slow cell metabolism in the biofilm, differential
expression of specific genes, and the presence of persister cells.
In addition, biofilms are composed of distinct subpopulations that
exhibit different physiological activity; cells in the biofilm interior
exhibit low metabolic activity, distinct from the high metabolism
of cells near the surface.[40,44,45] The dissimilar metabolic activity is thought to result from a concentration
gradient of O2 and nutrients, which are high at the biofilm
surface and low in the deeper layers of the biofilm.[45,46] Commercial antibiotics that interfere with cell replication (e.g.,
ciprofloxacin), or protein translation (e.g., tobramycin), preferentially
kill the metabolically active bacteria in the outer biofilm layers,
whereas cells in the biofilm interior survive,[44,47−49] despite the ability of both antibiotics to diffuse
into the inner regions of the biofilm.[44,50] In contrast,
some antimicrobials that affect membrane structure, such as colistin,
a “last-line” therapy to treat multidrug resistant infections,[51−53] can kill cells in the deeper biofilm layers.[49]We tested the susceptibility of mature biofilms to
treatment with analogues of 4-aminoisoindoline-1,3-dione using two
platforms, biofilms cultured at the solid–liquid interface
(flow cell biofilms) and biofilms cultured at the air–liquid
interface (pellicles). Biofilms of P. aeruginosa cells expressing an enhanced yellow fluorescent protein (EYFP) were
cultured in flow cells using AB minimal media supplemented with 15
μM Fe. 3-Day old biofilms were treated for 24 h with commercial
antibiotics or with 4-aminoisoindoline-1,3-dione analogues by flowing
AB media containing analogue or commercial antibiotic, 0.025% hypromellose
(HPMC), 1.5% DMSO and 15 μM Fe. In most experiments the concentration
of commercial antibiotics used was 25× or 50× MIC, and the
concentration of 4-aminoisoindoline-1,3-dione analogues was between
0.36× and 1.2× the IC50. The treated biofilms
were counterstained with the cell impermeable fluorescent nucleic
acid dye Sytox Red and then imaged with the aid of confocal laser
scanning microscopy (CLSM). Figure A depicts a representative image of the untreated control,
illustrating yellow-fluorescent viable cells and red-stained dead
cells and extracellular DNA. Figures B and 5C show representative
images depicting 4-day old biofilms tolerant to 24 h treatment with
ciprofloxacin or tobramycin, respectively, and Figure D shows 4-day old biofilms susceptible to
24 h treatment with colistin. In agreement with previously reported
observations,[49,54] treatment with ciprofloxacin
preferentially kills cells at the biofilm surface, leaving the interior
of the biofilm almost unaffected (Figure B). In contrast, treatment with colistin
preferentially kills bacteria in the biofilm interior, leaving the
biofilm surface less affected (Figure D). COMSTAT software was used to attempt a quantitative
comparison of the biofilm biomass by estimating the biovolume, which
is calculated as the overall volume/substratum area (μm3/μm2).[55] Comparing
the biofilm biomass as the ratio of (untreated biomass)/(treated biomass)
expressed as % survival (Figure E) shows that ∼20% of biomass remains viable
(yellow fluorescent) after treatment with colistin at 25× MIC.
In comparison, ∼60% and 70% of biomass remains viable after
treatment with 25× MIC ciprofloxacin or tobramycin, respectively.
Figure 5
Biofilms
cultured in flow cells are tolerant to ciprofloxacin and
tobramycin and susceptible to colistin. EYFP-expressing P. aeruginosa PAO1 biofilms were cultured for 3 days by flowing AB media supplemented
with 15 μM Fe and then treated for 24 h by flowing the same
media containing antibiotic. Biofilms were counterstained with Sytox
Red and imaged with the aid of CLSM. Top-down views (x–y plane) are depicted with side views (x–z plane) at the bottom. Viable
cell mass is in yellow and dead cells and extracellular DNA in red.
(A) Untreated (DMSO) control, (B) 25× MIC ciprofloxacin (19 μM),
(C) 25× MIC tobramycin (27 μM), (D) 25× MIC colistin
(20 μM). (E) The % survival obtained from viable biomass calculated
with the aid of COMSTAT software. The scale of the bars represents
20 μm. p < 0.01 denoted by ** and p < 0.001 by *** relative to untreated.
Biofilms
cultured in flow cells are tolerant to ciprofloxacin and
tobramycin and susceptible to colistin. EYFP-expressing P. aeruginosa PAO1 biofilms were cultured for 3 days by flowing AB media supplemented
with 15 μM Fe and then treated for 24 h by flowing the same
media containing antibiotic. Biofilms were counterstained with Sytox
Red and imaged with the aid of CLSM. Top-down views (x–y plane) are depicted with side views (x–z plane) at the bottom. Viable
cell mass is in yellow and dead cells and extracellular DNA in red.
(A) Untreated (DMSO) control, (B) 25× MIC ciprofloxacin (19 μM),
(C) 25× MIC tobramycin (27 μM), (D) 25× MIC colistin
(20 μM). (E) The % survival obtained from viable biomass calculated
with the aid of COMSTAT software. The scale of the bars represents
20 μm. p < 0.01 denoted by ** and p < 0.001 by *** relative to untreated.Having established that the biofilms are susceptible to colistin
and significantly tolerant to ciprofloxacin and tobramycin, we treated
similarly cultured 3-day old biofilms with KM-5-25 and KM-5-66 for 24 h. Compounds KM-5-25 and KM-5-66 are soluble in aqueous media to ∼110 and ∼80
μM, respectively. To ensure that the compounds remain soluble
during the 24 h treatment period, KM-5-25 was used at
concentrations 40 and 80 μM, equivalent to 0.6× and 1.2×
the IC50, and KM-5-66 was used at concentrations
15, 30, and 50 μM, equivalent to 0.36×, 0.7×, and
1.2× the IC50 (Table ). Representative CLSM images obtained after treating
3-day old biofilms with each of the analogues for 24 h show that both
compounds kill biofilm cells in a concentration dependent manner (Figure ). Treatment with
50 μM KM-5-66 elicits a similar level of killing
as treatment with 80 μM KM-5-25. The higher efficacy
exhibited by KM-5-66 agrees with its higher binding affinity
for BfrB and lower IC50. Inspection of the images obtained
upon treatment with the higher concentrations of KM-5-25 or KM-5-66 clearly shows that the inhibitors of the
BfrB-Bfd complex kill the cells in the interior of the biofilm, leaving
most of the viable cells located at the biofilm surface (Figure C,F). This pattern
of killing is reminiscent of previously reported observations showing
that treatment of biofilms with Ga3+ preferentially kills
cells in the inner portion of the biofilm.[56] The same authors concluded that cells in the biofilm interior are
more sensitive to Ga3+ because this population experiences
a more pronounced iron starvation. Therefore, we speculate that in
biofilms treated with KM-5-25 or KM-5-66 the internal biofilm population is more susceptible to iron limitation
caused by the nearly irreversible accumulation of iron in BfrB. It
is important to underscore that although the mechanisms whereby iron
starvation contribute to cell death in the biofilm interior are not
yet understood, the fact remains that perturbation of iron homeostasis,
either by systemic replacement of Fe3+ with Ga3+, or by selective inhibition of the BfrB-Bfd complex, leads to bacterial
cell death.
Figure 6
P. aeruginosa cells embedded in mature biofilms
grown in flow cells are susceptible to 4 aminoisoindoline-1,3-dione
analogues. EYFP-expressing P. aeruginosa PAO1
biofilms were cultured for 3 days by flowing AB media supplemented
with 15 μM Fe and then treated for 24 h with 4-aminoisoindoline-1,3-dione
analogue. Biofilms were counterstained with Sytox Red and imaged with
the aid of CLSM. Top-down views (x–y plane)
are depicted with side views (x–z plane) at
the bottom. Viable cell mass is in yellow and dead cells and extracellular
DNA in red. (A) Untreated (DMSO) control, (B) 0.6× IC50KM-5-25 (40 μM), (C) 1.2× IC50KM-5-25 (80 μM), (D) 0.36× IC50KM-5-66 (15 μM), (E) 0.7× IC50KM-5-66 (30 μM), and (F) 1.2× IC50KM-5-66 (50 μM). (G,H) The % survival obtained
from viable biomass calculated with the aid of COMSTAT software for
cells treated with KM-5-25 and KM-5-66,
respectively. The scale of the bars represents 20 μm. p < 0.01 denoted by ** and p < 0.001
by *** relative to untreated.
P. aeruginosa cells embedded in mature biofilms
grown in flow cells are susceptible to 4 aminoisoindoline-1,3-dione
analogues. EYFP-expressing P. aeruginosa PAO1
biofilms were cultured for 3 days by flowing AB media supplemented
with 15 μM Fe and then treated for 24 h with 4-aminoisoindoline-1,3-dione
analogue. Biofilms were counterstained with Sytox Red and imaged with
the aid of CLSM. Top-down views (x–y plane)
are depicted with side views (x–z plane) at
the bottom. Viable cell mass is in yellow and dead cells and extracellular
DNA in red. (A) Untreated (DMSO) control, (B) 0.6× IC50KM-5-25 (40 μM), (C) 1.2× IC50KM-5-25 (80 μM), (D) 0.36× IC50KM-5-66 (15 μM), (E) 0.7× IC50KM-5-66 (30 μM), and (F) 1.2× IC50KM-5-66 (50 μM). (G,H) The % survival obtained
from viable biomass calculated with the aid of COMSTAT software for
cells treated with KM-5-25 and KM-5-66,
respectively. The scale of the bars represents 20 μm. p < 0.01 denoted by ** and p < 0.001
by *** relative to untreated.To expand the observations made with flow cell biofilms into a
second biofilm model we also studied the susceptibility of biofilms
grown at the air–liquid interface (pellicles).[57,58] Pellicle biofilms (henceforth pellicles) are an attractive alternative
platform to study biofilms because pellicles are amenable to imaging
by CLSM and to harvesting, which can be desirable for additional biofilm
analysis.[26] To determine the susceptibility
of pellicles to antibiotics or inhibitors of the BfrB-Bfd complex,
we cultured 2-day old pellicles of EYFP-expressing P. aeruginosa cells in PI media supplemented with 20 μM Fe, as indicated
in the Methods. The pellicles were transferred
onto glass coverslips by allowing the surface of the coverslip to
contact a pellicle. The coverslip-adhered pellicles were subsequently
exposed to treatment solution (AB media supplemented with 15 μM
Fe, 0.025% HPMC, 1.5% DMSO, and antibiotic or analogue) for 24 h prior
to staining with Sytox Red and imaging with the aid of CLSM. The pellicle
biofilms are tolerant to ciprofloxacin and tobramycin at concentrations
25× and 50× the MIC (Figure B–E), as is evident by the yellow fluorescence
and near complete absence of red-stained dead cells. In contrast,
the pellicle biofilms are susceptible to colistin at concentrations
above 10× MIC (Figure F–H). Analysis of the images with COMSTAT, which allowed
a more quantitative comparison of cell survival upon treatment with
each of the antibiotics (Figure I), confirms tolerance to ciprofloxacin and tobramycin,
but sensitivity to colistin. Note that when the concentration of colistin
is 50× MIC the fluorescence signal from viable cells expressing
EYFP is undetectable. When pellicle biofilms are challenged with compound KM-5-25 of KM-5-66 bacterial cell death occurs
in a concentration dependent manner (Figure ). These results agree with the idea that
the 4-aminoisoindoline-1,3-derivatives penetrate the bacterial cell
and bind to their target in the P. aeruginosa cytosol. Inspection of the images and analysis with COMSTAT (Figure G and H) shows that
compound KM-5-66 is more efficacious than KM-5-25, observations that are consistent with the lower Kd and IC50 values measured for KM-5-66. It is also important to note that when compounds KM-5-25 and KM-5-66 are used at a concentration of 80 μM
and 50 μM, respectively (Figure G,H), which correspond approximately to 1.2× IC50, nearly 85% of the cells in the pellicle are killed. This
efficacy is similar that observed with colistin when used at 20 μM,
equivalent to 25× MIC (Figure I).
Figure 7
Pellicle biofilms are tolerant to ciprofloxacin and tobramycin,
and susceptible to colistin. Pellicles of P. aeruginosa PAO1 expressing EYFP were cultured in PI media supplemented with
20 μM Fe for 48 h, and then treated with antibiotics for 24
h. Pellicles were counterstained with Sytox Red and imaged with the
aid of CLSM. Images depict top-down views (squares) and side views
(rectangles) where viable cells are shown in yellow and dead cells
and extracellular DNA in red. (A) Untreated (DMSO) control, (B) 25×
MIC ciprofloxacin (19 μM), (C) 50× MIC ciprofloxacin (38
μM), (D) 25× MIC tobramycin (27 μM), (E) 50×
MIC tobramycin (54 μM), (F) 12.5× MIC colistin (10 μM),
(G) 25× MIC colistin (20 μM), (H) 50× MIC colistin
(40 μM). (I) The % survival obtained from viable biomass calculated
with the aid of COMSTAT software. The scale of the bars represents
20 μm. p < 0.001 denoted by *** relative
to untreated.
Figure 8
4-Aminoisoindoline-1,3-dione analogues kill P. aeruginosa cells embedded in pellicle biofilms.
Pellicles of P. aeruginosa PAO1 cells expressing
EYFP were cultured for 48 h in PI media supplemented
with 20 μM Fe, and then treated with KM-5-25 or KM-5-66 for 24 h. Pellicles were counterstained with Sytox
Red and imaged with the aid of CLSM. Images depict top-down views
(squares) and side views (rectangles) where viable cells are shown
in yellow and dead cells and extracellular DNA in red. (A) Untreated
(DMSO) control, (B) 0.6× IC50KM-5-25 (40 μM), (C) 1.2× IC50KM-5-25 (80 μM), (D) 0.36× IC50KM-5-66 (15 μM), (E) 0.7× IC50KM-5-66 (30 μM), and (F) 1.2× IC50KM-5-66 (50 μM). (G,H) The % survival obtained from viable biomass
calculated with the aid of COMSTAT software for pellicles treated
with KM-5-25 and KM-5-66, respectively.
The scale of the bars represents 20 μm. p <
0.01 denoted by ** and p < 0.001 by *** relative
to untreated.
Pellicle biofilms are tolerant to ciprofloxacin and tobramycin,
and susceptible to colistin. Pellicles of P. aeruginosa PAO1 expressing EYFP were cultured in PI media supplemented with
20 μM Fe for 48 h, and then treated with antibiotics for 24
h. Pellicles were counterstained with Sytox Red and imaged with the
aid of CLSM. Images depict top-down views (squares) and side views
(rectangles) where viable cells are shown in yellow and dead cells
and extracellular DNA in red. (A) Untreated (DMSO) control, (B) 25×
MIC ciprofloxacin (19 μM), (C) 50× MIC ciprofloxacin (38
μM), (D) 25× MIC tobramycin (27 μM), (E) 50×
MIC tobramycin (54 μM), (F) 12.5× MIC colistin (10 μM),
(G) 25× MIC colistin (20 μM), (H) 50× MIC colistin
(40 μM). (I) The % survival obtained from viable biomass calculated
with the aid of COMSTAT software. The scale of the bars represents
20 μm. p < 0.001 denoted by *** relative
to untreated.4-Aminoisoindoline-1,3-dione analogues kill P. aeruginosa cells embedded in pellicle biofilms.
Pellicles of P. aeruginosa PAO1 cells expressing
EYFP were cultured for 48 h in PI media supplemented
with 20 μM Fe, and then treated with KM-5-25 or KM-5-66 for 24 h. Pellicles were counterstained with Sytox
Red and imaged with the aid of CLSM. Images depict top-down views
(squares) and side views (rectangles) where viable cells are shown
in yellow and dead cells and extracellular DNA in red. (A) Untreated
(DMSO) control, (B) 0.6× IC50KM-5-25 (40 μM), (C) 1.2× IC50KM-5-25 (80 μM), (D) 0.36× IC50KM-5-66 (15 μM), (E) 0.7× IC50KM-5-66 (30 μM), and (F) 1.2× IC50KM-5-66 (50 μM). (G,H) The % survival obtained from viable biomass
calculated with the aid of COMSTAT software for pellicles treated
with KM-5-25 and KM-5-66, respectively.
The scale of the bars represents 20 μm. p <
0.01 denoted by ** and p < 0.001 by *** relative
to untreated.To assess the efficacy of antibiotics
and compounds with an approach
complementary to imaging with CLSM, we resorted to dispersing biofilm
cells for subsequent enumeration of viable cells (CFU/mL). To this
end, we cultured pellicle biofilms for 48 h in PI media containing
20 μM Fe and exposed them to AB media containing 15 μM
Fe and antibiotic or compound for 24 h, as described above. The biofilms
were then harvested, and the cells dispersed into sterile PBS by vortexing
in the presence of zirconia beads, prior to plating the cell suspensions
for subsequent enumeration of CFU/mL. The results from these experiments
are summarized in the plots of Figure which show the % cell survival of pellicle-embedded
cells after challenges with antibiotic or compound, calculated from
the fraction CFU/mL(after treatment)/CFU/mL(pretreatment). When colistin is used to treat the pellicles at concentrations
equivalent to 25× and 50× MIC, the treated biofilms exhibit
∼10% and ∼1% cell survival, respectively, relative to
the pretreated biofilm (Figure A), corroborating the sensitivity of the pellicles to colistin.
In contrast, challenging the pellicles with tobramycin (25× and
50× MIC) results in ∼70% survival relative to the pretreated
biofilm, and nearly identical cell survival relative to the untreated
(DMSO control) pellicles (Figure A). These observations, which are in good agreement
with those made with the aid of CLSM (Figure D–H) corroborate that the pellicles
are tolerant to tobramycin and sensitive to colistin. Interestingly,
attempts to enumerate cells after challenging the pellicles with ciprofloxacin
(25× or 50× MIC) resulted in extremely low CFU/mL, findings
which at first glance appear to be in conflict with the tolerance
of the biofilms to ciprofloxacin observed in the CLSM images (Figure B,C). To reconcile
these seemingly discrepant observations it is important to consider
that several stressors, including ciprofloxacin, can induce a dormancy
state in bacterial cells known as the viable but not culturable (VBNC)
state. A characteristic of cells in the VBNC state is their inability
to develop into colonies on routine culture media, even though the
cells remain viable for long periods of time.[59,60] Evidence that bacterial cells can enter the VBNC has been obtained
by several distinct methods,[60] one of which
is the utilization of bacteria engineered to constitutively express
bioluminescent proteins, and using the bioluminescence as a reporter
of metabolic activity. Studies conducted with P. aeruginosa showed that following treatment with ciprofloxacin the bioluminescence
emitted by P. aeruginosa cells decreased significantly
less than the viable cell counts (CFU/mL). The perceived reduction
in viable cell counts, which did not correlate with the relatively
high metabolic activity reported by the small decrease in bioluminescence,
indicated that challenges with ciprofloxacin induce P. aeruginosa cells to enter a VBNC state.[61,62] Our observations suggest
a similar situation. Imaging the pellicles with CLSM following the
24 h challenge with ciprofloxacin (Figure B,C) shows that most of the cells are metabolically
active (yellow fluorescent), but dispersion of the cells from the
pellicles for enumeration of CFU/mL shows a large reduction in culturable
cells relative to the untreated control. These observations strongly
suggest that treating the pellicles with ciprofloxacin induces the
cells to enter the VBNC state, thus rendering them tolerant to the
antibiotic. These findings, which highlight the complexities associated
with biofilm embedded cells, also underscore the importance of resorting
to more than one platform to study the efficacy of antibiofilm agents.
Figure 9
Assessment
of cell survival in pellicle biofilms by dispersing
and counting viable cells. EYFP-expressing P. aeruginosa PAO1 cells embedded in two-day old pellicles treated for 24 h with
antibiotic or 4-aminoisoindoline-1,3-dione derivatives were dispersed
for enumeration of viable culturable cells (CFU/mL). The % survival
is expressed as the ratio CFU/mL(after treatment)/CFU/mL(pretreatment). Pellicles were treated for 24 h with (A) tobramycin
(27 or 54 μM) or colistin (20 or 40 μM), concentrations
equivalent to 25× and 50× the corresponding MIC, (B) compound KM-5-25 (40 and 80 μM) concentrations equivalent to
0.6× and 1.2× IC50, and (C) compound KM-5-66 (15, 30, and 50 μM), concentrations equivalent to 0.36×,
0.7×, and 1.2× IC50. p <
0.001 denoted by *** relative to untreated.
Assessment
of cell survival in pellicle biofilms by dispersing
and counting viable cells. EYFP-expressing P. aeruginosa PAO1 cells embedded in two-day old pellicles treated for 24 h with
antibiotic or 4-aminoisoindoline-1,3-dione derivatives were dispersed
for enumeration of viable culturable cells (CFU/mL). The % survival
is expressed as the ratio CFU/mL(after treatment)/CFU/mL(pretreatment). Pellicles were treated for 24 h with (A) tobramycin
(27 or 54 μM) or colistin (20 or 40 μM), concentrations
equivalent to 25× and 50× the corresponding MIC, (B) compound KM-5-25 (40 and 80 μM) concentrations equivalent to
0.6× and 1.2× IC50, and (C) compound KM-5-66 (15, 30, and 50 μM), concentrations equivalent to 0.36×,
0.7×, and 1.2× IC50. p <
0.001 denoted by *** relative to untreated.Enumeration of CFU/mL was also carried out after challenging pellicles
with 4-aminoisoindoline-1,3-dione derivatives. Treating the pellicles
with KM-5-25 at concentrations equivalent to 0.6×
and 1.2× IC50 results in ∼38% and ∼25%
survival relative to cells in the pretreated biofilm (Figure B), while treating with KM-5-66 at concentrations equivalent to 0.3×, 0.6×,
or 1.2× IC50 results in approximately 57%, 21%, and
15% survival relative to cells in the pellicles prior to treatment
(Figure C). These
observations, which are in good agreement with the efficacy of the
compounds evaluated by COMSTAT analysis of the CLSM images, corroborate
the bactericidal activity of the compounds against P. aeruginosa biofilms, and provide additional evidence indicating that KM-5-66 used at 50 μM (1.2× IC50) exhibits
nearly the same efficacy as colistin used at 20 μM (25×
MIC). We also used the strategy of dispersing and counting viable
cells to compare the relative efficacy of analogues 11, 16, KM-5-25, and KM-5-66. To this end, pellicles formed by P. aeruginosa PAO1 cells were treated (24 h) with each of the compounds at a concentration
of 50 μM. The results (Figure S6)
show that the compound activity against biofilm (KM-5-66 > KM-5-25 > 16 > 11) track
with the Kd and IC50 values
(Table ). Taken together,
these findings suggest that additional modifications made to the structures
of KM-5-25 or KM-5-66 which improve the
binding affinity for BfrB have the potential to produce molecules
with similar or better efficacy toward biofilms than colistin.The results from experiments aimed at determining the efficacy
of the 4-aminoisoindoline-1,3-dione derivatives presented so far have
been conducted with the reference strain P. aeruginosa PAO1. To investigate whether the compounds are also active against
other strains of P. aeruginosa, we cultured
pellicles of several clinical isolates from JMI Laboratories. Isolates
PA_1081725 and PA_1076058 were chosen for additional testing because
these strains exhibit relatively high MIC values for several antibiotics
(Figure C) and form
robust pellicles under the same culture conditions used to grow pellicle
biofilms of P. aeruginosa PAO1. Challenging
the pellicles formed by PA_1081725 and PA_1076058 with analogues KM-5-25 or KM-5-66 at concentrations equivalent
to 1.2× IC50 elicits approximately 80% reduction of
viable cells (Figure A,B), indicating that the activity of the 4-aminoisoindoline-1,3-dione
analogues is not unique to biofilms formed by the P. aeruginosa PAO1 strain. To gain a broader understanding of the potential activity
spectrum of the BfrB-Bfd inhibitors against P. aeruginosa strains, BLASTp[63] was used to find homologues
of BfrB and Bfd sequences in the >4400 P. aeruginosa genomes in the Pseudomonas Genome Database.[64] The results reveal two important facts: (i) The bfrB and bfd genes are adjacent to one
another in all the P. aeruginosa strains. (ii) There is an extremely high level of conservation among
the bfd and bfrB sequences. These
findings allow us to predict that the structures of the BfrB and Bfd
proteins, as well as the structures of the BfrB-Bfd complexes, are
highly conserved across P. aeruginosa strains,
thus suggesting that the 4-aminoisoindoline-1,3-dione derivatives
can be expected to be broadly active against P. aeruginosa.
Figure 10
4-Aminoisoindoline-1,3-dione analogues are likely broadly active
against P. aeruginosa strains. Two-day old pellicle
biofilms formed by P. aeruginosa clinical isolates
(PA_1081725 and PA_1076058) were challenged for 24 h with 4-aminoisoindoline-1,3-dione
derivatives prior to dispersing the cells for enumeration of viable
culturable cells (CFU/mL). The % survival is expressed as the ratio
of CFU/mL(after treatment)/CFU/mL(pretreatment). Pellicles of (A) PA_1081725 or (B) PA_1076058 were treated with
concentrations equivalent to 1.2× IC50 of KM-5-25 (80 μM), or KM-5-66 (50 μM). (C) Antibiotic
susceptibility of clinical isolates PA_1081725 and PA_1076058. p < 0.001 denoted by *** relative to untreated.
4-Aminoisoindoline-1,3-dione analogues are likely broadly active
against P. aeruginosa strains. Two-day old pellicle
biofilms formed by P. aeruginosa clinical isolates
(PA_1081725 and PA_1076058) were challenged for 24 h with 4-aminoisoindoline-1,3-dione
derivatives prior to dispersing the cells for enumeration of viable
culturable cells (CFU/mL). The % survival is expressed as the ratio
of CFU/mL(after treatment)/CFU/mL(pretreatment). Pellicles of (A) PA_1081725 or (B) PA_1076058 were treated with
concentrations equivalent to 1.2× IC50 of KM-5-25 (80 μM), or KM-5-66 (50 μM). (C) Antibiotic
susceptibility of clinical isolates PA_1081725 and PA_1076058. p < 0.001 denoted by *** relative to untreated.
4-Aminoisoindoline-1,3-dione Derivatives
Inhibit Iron Mobilization
from BfrB in P. aeruginosa Cells
The
results presented above demonstrate that the 4-aminoisoindoline-1,3-dione
derivatives can kill cells in mature biofilms. To demonstrate that
the bactericidal activity is likely a result of the compounds engaging
BfrB in the P. aeruginosa cytosol, inhibiting
the BfrB-Bfd complex and blocking iron mobilization from the bacterioferritin
in the P. aeruginosa cytosol, we carried out
experiments aimed at visualizing the iron stored in BfrB. These experiments
capitalize on a strategy we reported previously to demonstrate that
the Δbfd mutant of P. aeruginosa irreversibly accumulates iron in BfrB[23] and to show that analogue 16 inhibits iron mobilization
from BfrB in planktonic cells.[25] To visualize
BfrB-stored iron in biofilm-embedded cells, 2-day old pellicles of P. aeruginosa PAO1 cells were treated for 24 h with
analogue KM-5-25 (40 μM) or KM-5-66 (20 μM) at a concentration predicted to kill approximately
50% of the cells in the biofilm. The treated pellicles were dispersed
in sterile PBS and the cell suspension was harvested by centrifugation
after a small aliquot had been sampled to enumerate viable cells.
To visualize iron stored in BfrB the harvested cells were lysed, the
lysate solution supernatant was clarified by centrifugation and then
loaded onto native PAGE gels for separation and subsequent staining
with Ferene S, which reacts with iron to develop a blue color. Since
the viable cell count dispersed from the pellicle biofilms treated
with KM-5-25 or KM-5-66 was 42% and 37%
of the cells in the untreated pellicle (Figure A), the clarified lysate supernatants from
the untreated control were diluted approximately 2-fold prior to loading
the native gels. Results obtained with a representative gel are shown
in Figure B, where
it can be observed that lanes loaded with lysate solutions from pellicles
treated with analogues KM-5-25 or KM-5-66 exhibit significantly higher Ferene S stain intensity than the lane
loaded with lysate solution from the untreated pellicle. To enable
quantitative comparison we measured the relative intensities of the
Ferene S-stained bands with the aid of ImageJ. Comparing the resultant
peak areas (Figure C) shows that BfrB from the cells treated with KM-5-25 or KM-5-66 has ∼3-fold more iron relative to
BfrB from cells in the untreated pellicles. These findings provide
strong evidence indicating that compounds KM-5-25 and KM-5-66 bind BfrB in the P. aeruginosa cytosol, inhibit the formation of the BfrB-Bfd complex required
to mobilize iron from BfrB, and lead to nearly irreversible iron accumulation
in BfrB. Consistent with the nearly irreversible accumulation of iron
in BfrB in cells treated with KM-5-25 or KM-5-66, quantification of the total intracellular iron and normalizing
the values to viable cell counts demonstrates that P. aeruginosa cells dispersed from pellicles treated with KM-5-25 or KM-5-66 harbor ∼2.5-fold more intracellular
iron than cells obtained from untreated biofilms (Figure D). Taken together, these
observations support the idea that 4-aminoisoindoline-1,3-derivatives
dysregulate iron homeostasis by inhibiting the BfrB-Bfd complex, causing
the accumulation of unusable iron in the bacterial cell.
Figure 11
4-Aminoisoindoline-1,3-dione
analogues penetrate the P. aeruginosa cell,
bind BfrB, and inhibit mobilization of BfrB-stored iron. (A)
Treating pellicles with 0.6× IC50KM-5-25 (40 μM) or 0.5× IC50KM-5-66 (20
μM) for 24 h reduces the number of viable cells to <50%.
(B) The iron stored in BfrB in the viable cells was visualized with
the aid of native PAGE gels stained with Ferene S, which stains the
iron in the interior cavity of BfrB. Recombinant BfrB (BfrBrec) was used as a standard for the electrophoretic mobility of BfrB.
The lane corresponding to untreated control was loaded with 0.5×
the volume of the lanes loaded with lysates from treated pellicles
to account for the ∼2-fold larger number of viable cells in
the untreated pellicles. Lanes loaded with treated pellicle lysates
show greater accumulation of iron in BfrB relative to untreated cells.
(C) Peak areas obtained from densitometry analysis (ImageJ) of the
bands in the native PAGE gel of panel B indicate that there is ∼3-fold
more iron stored in BfrB in the treated cells relative to the untreated
control. (D) Analysis of total intracellular iron levels normalized
to CFU/mL indicates ∼2.5-fold higher iron levels in the pellicle-embedded
cells treated with the 4-aminoisoindoline-1,3-dione analogues relative
to untreated control. Panel B shows results from a representative
experiment from 3 biological replicates. Panels A, C, and D show the
average of 3 biological replicates. p < 0.001
is denoted by *** relative to untreated.
4-Aminoisoindoline-1,3-dione
analogues penetrate the P. aeruginosa cell,
bind BfrB, and inhibit mobilization of BfrB-stored iron. (A)
Treating pellicles with 0.6× IC50KM-5-25 (40 μM) or 0.5× IC50KM-5-66 (20
μM) for 24 h reduces the number of viable cells to <50%.
(B) The iron stored in BfrB in the viable cells was visualized with
the aid of native PAGE gels stained with Ferene S, which stains the
iron in the interior cavity of BfrB. Recombinant BfrB (BfrBrec) was used as a standard for the electrophoretic mobility of BfrB.
The lane corresponding to untreated control was loaded with 0.5×
the volume of the lanes loaded with lysates from treated pellicles
to account for the ∼2-fold larger number of viable cells in
the untreated pellicles. Lanes loaded with treated pellicle lysates
show greater accumulation of iron in BfrB relative to untreated cells.
(C) Peak areas obtained from densitometry analysis (ImageJ) of the
bands in the native PAGE gel of panel B indicate that there is ∼3-fold
more iron stored in BfrB in the treated cells relative to the untreated
control. (D) Analysis of total intracellular iron levels normalized
to CFU/mL indicates ∼2.5-fold higher iron levels in the pellicle-embedded
cells treated with the 4-aminoisoindoline-1,3-dione analogues relative
to untreated control. Panel B shows results from a representative
experiment from 3 biological replicates. Panels A, C, and D show the
average of 3 biological replicates. p < 0.001
is denoted by *** relative to untreated.
4-Aminoisoindoline-1,3-dione Derivatives Enhance the Efficacy
of Colistin and Tobramycin against Biofilm-Embedded Cells
As demonstrated above and in previous reports,[65,66] mature biofilms formed by P. aeruginosa cells
are susceptible to colistin and tolerant to tobramycin. Since these
biofilms are also susceptible to the 4-aminoisoindoline-1,3-dione
inhibitors of the BfrB-Bfd complex, we asked whether these compounds
would enhance the efficacy of colistin and tobramycin. To answer this
question, we cultured 2-day old pellicle biofilms of EYFP-expressing P. aeruginosa PAO1 and treated them for 24 h with colistin
alone, compound alone (KM-5-25 or KM-5-66), and with a combination of colistin and compound. In the combination
treatment experiments, the concentration of compound was kept constant
(1.2× IC50), while colistin was used at two different
concentrations, equivalent to 25× and 50× MIC (Figure A). Treatment with
each of the compounds or with colistin alone caused a reduction of
viable cells similar to that reported in Figure A. Challenging the pellicles with a combination
of colistin and compound, however, causes a significant additional
reduction in the number of viable cells (Figure A): the combination treatment with KM-5-66 results in ∼0.3% survival when colistin is
present at 25× MIC, and ∼0.02% survival when colistin
is used at 50× MIC, which correspond to approximately 1.7 log
and 1.9 log reduction of viable cells relative to treatment with colistin
alone. In comparison, the combination treatment with KM-5-25 results in ∼1% survival when colistin is used 25× MIC
and ∼0.5% survival when colistin is present at 50× MIC,
which correspond to nearly 1 log and 0.7 log reduction of viable cells,
respectively, compared to colistin alone. Encouraged by these results
we tested whether the 4-aminoisoindoline-1,3-dione derivatives can
also enhance the bactericidal activity of tobramycin. The results
are shown in Figure B: the combination treatment with KM-5-25 results in
∼0.5% survival when tobramycin is used at 25× MIC and
∼0.003% survival when tobramycin is present at 50× MIC,
which correspond to approximately 2.5 log and 4.7 log reduction of
viable cells when compared to treatment with tobramycin alone. The
combination treatment with KM-5-66 results in 5% survival
when tobramycin is present at 25× MIC and 1% survival when tobramycin
is used at 50× MIC, which correspond to approximately 1.5 log
and 2 log reduction in viable cells relative to treatment with tobramycin
alone. It is interesting to note that compound KM-5-66 is more effective at enhancing the efficacy of colistin (Figure A), whereas compound KM-5-25 is more effective at enhancing the efficacy of tobramycin
(Figure B). Additional
studies are clearly required to understand the underlying reasons.
Figure 12
4-Aminoisoindoline-1,3-dione
derivatives enhance the efficacy of
colistin and tobramycin against P. aeruginosa biofilms. Two-day old pellicles of EYFP-expressing P. aeruginosa PAO1 were treated for 24 h with (A) colistin alone 25× MIC
(20 μM), or 50× MIC (40 μM), KM-5-25 (80 μM) or KM-5-66 (50 μM) alone, equivalent
to 1.2× IC50, or a combination of colistin and KM-5-25 or KM-5-66, and (B) tobramycin alone
25× MIC (27 μM) or 50× MIC (40 μM), KM-5-25 or KM-5-66 alone at a concentration equivalent to 1.2×
IC50, or a combination of tobramycin and KM-5-25 or KM-5-66. The % survival is expressed as the ratio
CFU/mL(after treatment)/CFU/mL(pretreatment). p < 0.001 is denoted by *** in the combination
treatment relative to treatment with antibiotic alone.
4-Aminoisoindoline-1,3-dione
derivatives enhance the efficacy of
colistin and tobramycin against P. aeruginosa biofilms. Two-day old pellicles of EYFP-expressing P. aeruginosa PAO1 were treated for 24 h with (A) colistin alone 25× MIC
(20 μM), or 50× MIC (40 μM), KM-5-25 (80 μM) or KM-5-66 (50 μM) alone, equivalent
to 1.2× IC50, or a combination of colistin and KM-5-25 or KM-5-66, and (B) tobramycin alone
25× MIC (27 μM) or 50× MIC (40 μM), KM-5-25 or KM-5-66 alone at a concentration equivalent to 1.2×
IC50, or a combination of tobramycin and KM-5-25 or KM-5-66. The % survival is expressed as the ratio
CFU/mL(after treatment)/CFU/mL(pretreatment). p < 0.001 is denoted by *** in the combination
treatment relative to treatment with antibiotic alone.The observations above, which indicate that the iron limitation
induced by inhibitors of the BfrB-Bfd complex can increase the efficacy
of colistin and tobramycin against biofilms, are in good agreement
with previous studies showing that the Fe chelator HBDE is an effective
colistin adjunct against P. aeruginosa,[67] and the iron chelators deferoxamine and deferasirox
increase the efficacy of tobramycin against P. aeruginosa biofilms.[68] When taken together, the
observations made in the presence of HBDE, deferoxamine, deferasirox
or 4-aminoisoindoline-1,3-dione derivatives, strengthen the idea that
inducing intracellular iron limitation is probably a viable strategy
to enhance the efficacy of colistin or tobramycin against biofilms.
Since colistin is often used as one of the very few therapeutic options
available to combat multidrug resistant Gram-negative organisms such
as Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae,[69,70] it is encouraging that small molecule inhibitors of the BfrB-Bfd
complex are capable of increasing the effectiveness of colistin against P. aeruginosa. In this context, it is noteworthy that
the bfr and bfd genes in A. baumannii and K. pneumoniae strains are contiguous, as is the case in the >4000 P. aeruginosa genomes currently available in the Pseudomonas Genome Data Base,
because it suggests that the function of the Bfr-Bfd complex in P. aeruginosa is conserved in A. baumannii and K. pneumoniae. Moreover, amino acid sequence
alignment with the aid of Clustal Omega[71] reveals very high conservation in the amino acid sequences of Bfr
and Bfd proteins from P. aeruginosa, A. baumannii and K. pneumoniae (Figure S7–S8). Importantly, the
amino acids identified as hot spot residues in the BfrB-Bfd complex
of P. aeruginosa(33) are highly conserved in the Bfr and Bfd sequences of A. baumannii and K. pneumoniae, suggesting that the 4-aminoisoindoline-1,3-dione
derivatives designed to inhibit the BfrB-Bfd interaction in P. aeruginosa are likely to act similarly in A. baumannii and K. pneumoniae.
Concluding Remarks
Bacterial iron metabolism is a vulnerability
that may be exploited
in the development of new antimicrobial therapies. The field has centered
on four major avenues: (i) The development of siderophore-antibiotic
conjugates aims at capitalizing on siderophore uptake receptors to
enhance antibiotic cell penetration.[72,73] (ii) The sequestration of iron with the aid of chelators is also directed
at depleting intracellular iron, and whereas iron chelation has been
shown to lead to biofilm dispersion or to prevent biofilm maturation
in vitro,[35,37,48,68,74] a potential concern
is the probability of secondary infections fueled by the chelated
iron.[75,76] (iii) The perturbation
of heme uptake or heme degradation aims at denying pathogens from
using heme, a rich iron source during infection.[77,78] (iv) The perturbation of iron homeostasis with
Ga3+ aims at inducing iron limitation by replacing Fe3+ in the active site of enzymes with Ga3+ which
cannot support the rich redox chemistry typical of iron.[79,80] Systemic Ga3+ treatment has been shown to improve lung
function in patients with chronic P. aeruginosa infection.[56] Our work, which aims at
adding an entirely new strategy for exploiting the bacterial iron
metabolism vulnerability, is directed at inhibiting the mobilization
of iron from bacterioferritin. Blocking iron mobilization from BfrB
by deletion of the bfd gene has been shown to elicit
a breakdown in iron homeostasis due to the irreversible accumulation
of unusable iron in BfrB, which causes cytosolic iron deficiency.[23] Because of the relatively high iron requirement
necessary to support the biofilm lifestyle, the intracellular iron
deficiency induced in the Δbfd cells has been
shown to result in poorly developed biofilms.[26] Encouraged by these findings our laboratories have pursued drug
discovery strategies to discover small molecule inhibitors of the
BfrB-Bfd complex, which led us to a series of 4-aminoisoindoline-1,3-dione
derivatives capable of penetrating the P. aeruginosa cell envelope, inhibiting the BfrB-Bfd complex and eliciting a cell
growth defect in planktonic cells.[25] Additional
structural manipulation of these 4-aminoisoindoline-1,3-dione derivatives
led us to analogues with increased affinity for BfrB and enhanced
bacteriostatic activity against planktonic P. aeruginosa cells (Table ).
Testing these new derivatives against mature biofilms revealed that
these small molecules inhibit iron mobilization from BfrB in biofilm-embedded
cells (Figure )
and kill P. aeruginosa cells in mature biofilms
cultured in flow cells (Figure ) or in pellicles cultured at the air–liquid interface
(Figure ). These findings
demonstrate the potential of small molecules developed to inhibit
the BfrB-Bfd complex in P. aeruginosa as important
tools to expose a rare weakness of biofilms. It is also encouraging
that the small molecule inhibitors of the BfrB-Bfd complex increase
the effectiveness of tobramycin and colistin because the latter is
often used as one of the very few therapeutic options available to
combat multidrug resistant Gram-negative organisms.[69,70] The high level of conservation in the Bfr and Bfd sequences from P. aeruginosa, A. baumannii,
and K. pneumoniae (Figure S7–S8) suggests that the compounds developed to block
the BfrB-Bfd complex in P. aeruginosa may exert
similar activity in A. baumannii and K. pneumoniae cells.
Methods
Chemicals,
Bacterial Strains, and Growth Media
Chemicals
were purchased from Fisher Scientific unless otherwise stated. P. aeruginosa PAO1 was obtained from the University
of Washington Genome center.[81] The PAO1
strain expressing enhanced yellow fluorescent protein (EYFP) was prepared
previously.[26] Clinical isolates of P. aeruginosa were purchased from JMI Laboratories
(North Liberty, IA, USA). IC50 determinations were carried
out in defined media (50 mM KH2PO4 (Sigma-Aldrich)
7.5 mM (NH4)2SO4 (Sigma, Life Sciences),
0.1% (w/v) glucose (Acros Organics, 99+%), 0.5 mM MgSO4·7H2O (Sigma-Aldrich, 99+%), 5% v/v nonessential
amino acids (Gibco), 2% v/v essential amino acids (Gibco), 4 μM
(NH4)2Fe(SO4)2, and 0.025%
(w/v) hypromellose (HPMC, Sigma-Aldrich), pH 7.0. The media was filter-sterilized
by passing through a 0.2 μm cellulose acetate membrane syringe
filter (VWR). Starter cultures of P. aeruginosa PAO1 in 5 mL LB media were grown for 13 h in 50 mL conical tubes
at 37 °C and 220 rpm. For biofilm experiments, a EYFP-expressing P. aeruginosa strain was routinely grown in Pseudomonas Isolation (PI) media (20 g L–1 peptone, 0.3 g L–1 MgCl2·6H2O,
10 g L–1 K2SO4, 25 mg L–1 irgasan, and 20 mL L–1 glycerol,
pH 7.0). Starter cultures were grown from a single colony at 37 °C
and shaking at 220 rpm for 14 h in 5 mL PI media supplemented with
10 μM Fe. Pellicle biofilms were cultured for 48 h at 30 °C
in PI media supplemented with 20 μM Fe. Surface-attached biofilms
were cultured in AB minimal media[82] supplemented
with trace metals [0.15 μM (NH4)2MoO4, 3 μM CuSO4, 2 μM Co(NO3)2, 9.4 μM Na2B4O7, and 7.6 μM ZnSO4], 3 mM glucose and 15 μM
Fe. Iron supplementation was carried out by addition of a small volume
of filter-sterilized 10 mM (NH4)2Fe(SO4)2 (pH ∼ 2.0) solution. The antibiotics ciprofloxacin,
colistin and tobramycin were used at concentrations equivalent to
25× and 50× the reported MCI:[83] ciprofloxacin MIC = 0.25 μg/mL = 0.75 μM; tobramycin
MIC = 0.5 μg/mL = 1.07 μM; colistin MIC = 1 μg/mL
= 0.79 μM. Compound stock solutions (100 mM or 10 mM) in DMSO
(Sigma-Aldrich) were prepared weekly and stored at 4 °C. Solutions
used to treat biofilms or planktonic cells include 0.025% (w/v) HPMC,
and 1.5% or 2% DMSO (Sigma-Aldrich) to prevent aggregation of the
analogues in aqueous solution.
Synthesis and Preparation
of 4-Aminoisoindoline-1,3-dione Derivatives
Experimental
details of the synthetic protocols developed to prepare
the 4-aminoisoindoline-1,3-dione derivatives to be tested as inhibitors
of the BfrB-Bfd complex, as well as 1H, 13C
NMR and MS data, are presented in the Supporting Information.
Measurement of Dissociation Constant (Kd)
Dissociation constants for the interaction
between
BfrB and 3-aminoisoindoline-1,3-dione derivatives (Table , Figure S1) were measured in vitro with a fluorescence polarization
method based on the intrinsic fluorescence of the isoindoline-1,3-dione
moiety, as described previously.[25]
Measurement
of Half Maximal Inhibitory Concentration (IC50)
IC50 values (Table , Figure S1) were
determined as reported previously[25] with
small modifications. In brief: precultures of P. aeruginosa PAO1 (5 mL) were grown in LB media for 13 h at 37 °C and 220
rpm in 50 mL conical tubes (VWR International, PA). The cells were
centrifuged for 5 min at 4000 rpm and 4 °C, washed two times
and then diluted in buffer (100 mM KH2PO4 and
15 mM (NH4)2SO4) to an optical density
at 600 nm (OD600) of 0.1. A small volume of compound stock
solution (10 mM) was transferred to a microcentrifuge tube, initially
diluted with DMSO to 20 μL, and then diluted to 1 mL with preculture
cell suspension in defined media with OD600 = 0.0001, so
the final DMSO concentration is 2%. The resultant cell suspension
(200 μL) was transferred to a clear-bottom polystyrene 96-well
plate (VWR) covered with a lid and incubated at 35 °C and 205
cpm for 24 h in a Synergy H1 microplate reader (Biotek Instruments
Inc., Vermont). The cell cultures were serially diluted and then plated
on PI Agar (PIA; BD biosciences) plates for enumeration of viable
cells (CFU/mL). The % growth was calculated from the ratio CFU/mL(treated)/CFU/mL(untreated control). To calculate
the IC50 values, the % growth was plotted as a function
of compound concentration, expressed as log[compound] (μM),
and fitted to the 4-parameter logistic model describing the sigmoid-shaped
response pattern (eq ),[84] where b is the slope
factor, max is the upper asymptote (plateau), and min is the lower
asymptote. Values are the average and standard deviation from three
independent experiments.
Analysis
of Secreted Pyoverdine in Planktonic Cultures
These experiments
were conducted in 96 well plates as described above
for the determination of IC50, except that the cells were
cultured in M63 media (2 g/L (NH4)2SO4, 13.6 g/L KH2PO4 (Sigma-Aldrich), 2 g/L glucose,
4 g/L citric acid, 5 g/L technical grade casamino acids (BD Scientific),
0.24 g/L MgSO4 (Alfa Aesar), and 0.05% (w/v) HPMC, pH 7.0
adjusted with KOH). Cultures of P. aeruginosa PAO1 treated with KM-5-25 (70 μM) or KM-5-66 (50 μM) were grown for 27 h prior to diluting the contents
of each well in PBS (pH 7.4) and plating the cells on PIA plates for
enumeration of CFU/mL. The 500-fold diluted solution was clarified
by centrifugation and the pyoverdine in the cell-free supernatant
was analyzed by acquiring fluorescence emission spectra (430–550
nm) with excitation at 400 nm (10 nm slit width) and emission at λmax = 460 nm (10 nm slit width) using a PerkinElmer LS50B spectrophotometer.
Flow Cell Biofilm Assays
Surface-attached biofilms
of P. aeruginosa PAO1 cells expressing EYFP
were grown on flow cells with an 800 μm channel depth (μ-slide
I0.8 Luer, Ibidi) using an automated perfusion system (Ibidi,
Munich, Germany), as described previously.[26] Briefly, the flow cell was inoculated with 200 μL of an overnight
culture diluted to OD600 = 0.5, followed by 1 h incubation
at 30 °C to allow bacterial cell attachment. The μ-slide
was connected to the Ibidi Pump System and the biofilms were cultured
for 3 days at 30 °C while flowing AB minimal media containing
15 μM Fe. The experimental shear stress was 0.14 dyn/cm2 (shear rate = 14 s–1, pressure = 7.1 mbar,
flow rate = 0.4 mL/min) and the switch time was set to 540 s. The
biofilms were treated for 24 h by flowing AB minimal media supplemented
with 15 μM Fe, 0.025% HPMC, 1.5% DMSO and commercial antibiotics
or 4-aminoisoindoline-1,3-dione derivatives in the concentrations
indicated in the corresponding figure captions. During biofilm growth
and challenge with antibacterial, the culture medium in the reservoirs
was removed every 12 h and replaced with fresh prewarmed medium. Prior
to imaging with the aid of CLSM the biofilms were stained with 4 mL
of 2.5 nM Sytox Red (Invitrogen Life Technologies), a cell impermeable
fluorescent nucleic acid dye that stains dead cells and extracellular
DNA,[85] for 20 min (switch time = 200 s)
and then washed with AB media for 20 min to remove excess fluorescent
dye. The biofilms were imaged with the aid of a Leica TCS SP8 confocal
microscope (Leica Microsystems, Germany) using a HC PL apo CS2 63
× /1.4 oil objective. For detecting the EYFP fluorescence the
laser line was set at 506 nm and the emission range to 520–610
nm. Sytox Red fluorescence was detected with excitation at 631 nm
and emission range 637–779 nm. Image stacks were acquired with
a z-step size of 0.3 μm at randomly chosen
positions. The Leica Application Suite X (LAS-X) software was used
for image stack processing.[55] Quantitative
analysis of biofilm biomass was performed using the COMSTAT computer
program[55] and the Otsu method of automatic
thresholding.[86]
Pellicle Biofilm Assays
Pellicle biofilms of EYFP-expressing P. aeruginosa PAO1 or clinical isolates were grown
in PI media supplemented with 20 μM Fe. Starter cultures were
diluted to OD600 = 0.001 in 4 mL media, placed in 35 ×
10 mm Petri dishes and incubated statically at 30 °C for 48 h.
The pellicles were transferred onto circular (1.5 cm diameter) glass
coverslips by gently allowing the surface of a coverslip to contact
a pellicle. The pellicle-adhered coverslip was washed in PBS and then
deposited on top of 1.5 mL AB challenge media contained in a well
of a 12-well microplate, with the pellicle exposed to the media. Challenge
media consists of AB minimal media supplemented with 15 μM Fe,
0.025% HPMC, 1.5% DMSO, and commercial antibiotic or 4-aminoisoindoline-1,3-dione
derivative, used in the concentrations specified in the figure captions.
The 4-aminoisoindoline-1,3-dione derivatives were prepared as 10 mM
stock solutions in DMSO and then diluted in culture media to the appropriate
concentrations. The coverslip-adhered pellicles were exposed to challenge
media at 30 °C for 24 h, changing the challenge media every 12
h by transferring the pellicle-adhered coverslip to a new plate containing
prewarmed challenge media.Prior to imaging with the aid of
CLSM, pellicles formed by EYFP-expressing PAO1 cells were washed with
PBS and then stained by placing the coverslip-adhered pellicles in
1 mL of PBS containing 2.5 nM Sytox Red (20 min). Excess fluorescent
dye was washed with PBS, the coverslip was mounted on a glass slide
using 5 μL SlowFade (Invitrogen Life Technologies) and the edges
sealed with fingernail polish. CLSM image stacks (z-step size of 0.3 μm) were acquired with the aid of a Leica
TCS SP8 microscope, as described above. Quantitative analysis was
performed by determination of pellicle biomass using COMSTAT[55] and the Otsu method of automatic thresholding.[86]
Determination of Viable Cells in Pellicle
Biofilms
Pellicle biofilms were grown as described above.
Planktonic and loosely
attached cells were washed (3 times) by immersing the coverslip-adhered
pellicles (biofilm facing up) into a well of a 12-well plate containing
3 mL PBS, and incubating (5 min) with gentle rocking. To remove the
pellicle from the coverslip, break the extracellular matrix and release
cells from the biofilm, the coverslip-adhered pellicle was placed
in a 50 mL conical tube containing a 2 mL suspension of zirconia beads
(0.1 mm diameter, BioSpec Products), 10 mL PBS, 0.2 μg/mL alginate
lyase and 0.2 μg/mL DNase. The resultant mixture was incubated
at room temperature for 3 min, followed by vigorous vortexing for
4 min. After sedimentation of the zirconia beads, a 100 μL aliquot
was used for serial dilution and plating on PIA plates for subsequent
enumeration of viable cells (CFU/mL).
Imaging of Iron Stored
in BfrB and Analysis of Total Intracellular
Iron in Biofilm-Embedded Cells
Pellicle biofilms were grown
for 48 h as described above. The pellicles were transferred onto square
(2 × 2 cm) glass coverslips by gently contacting the pellicle
with the coverslip. The pellicle-adhered coverslip was washed in PBS
and then placed in a 50 mL conical tube containing 2 mL suspension
of zirconia beads, 15 mL PBS, 0.2 μg/mL alginate lyase and 0.2
μg/mL DNase; the resultant mixture was incubated (3 min) at
room temperature, and then vortexed vigorously for 4 min. After the
zirconia beads had sedimented, a 100 μL aliquot was sampled
from the cell suspension for plating and enumeration of viable cells
and a 14 mL sample was used to harvest the cells by centrifugation
(20 min, 400 rpm). The cell pellet was resuspended in 1 mL PBS, transferred
to a 1.5 mL microcentrifuge tube, centrifuged for 10 min at 12 500
rpm at 4 °C and the cell pellet frozen at −80 °C.
The frozen cells were subjected to three freeze–thaw cycles
and then lysed by addition of 200 μL of lysis buffer (50 mM
Tris-HCl buffer (pH 8.0) containing 10% (v/v) glycerol, 20 mg/mL lysozyme,
0.2 mg/mL DNase, 0.1 M NaCl, 1 mM MgSO4 and 1% (v/v) Triton-X100)
and incubated at ambient temperature (30 min) and at 37 °C (30
min). Imaging of iron in BfrB was carried out as previously reported:[23] lysate suspensions were clarified by centrifugation
(10 min at 12 500 rpm), mixed with 10 μL loading dye
(5.9 mL deionized water, 0.5 mL glycerol, 0.4 mL β-mercaptoethanol,
0.4 mL 1% (w/v) bromophenol blue, and 0.5 mL 1 M Tris–HCl (pH
6.8), and loaded onto 1.5 mm-thick native PAGE gels (4% stacking gel,
8% resolving gel). Electrophoresis was carried out at 60 V and 4 °C
for 9 h, and the gels were stained in the dark by immersion (10 min)
in a solution containing 0.049 g Ferene S, 250 μL thioglycolic
acid, 2.4 mL acetic acid and 100 mL deionized water. Levels of total
intracellular iron were determined as reported previously:[23,87] The cell pellets were treated with 500 μL of freshly prepared
digestion reagent (0.6 N HCl, 2.25% (w/v) KMnO4 in water),
thoroughly mixed by vortexing, and then incubated at 65 °C for
3.5 h. The resultant solutions were cooled to ambient temperature,
treated with 100 μL of iron detection reagent (6.5 mM Ferene
S, 15.4 mM neocuproine, 2 M ascorbic acid, and 5 M ammonium acetate),
incubated for 30 min at ambient temperature and centrifuged for 5
min at 12500 rpm. The iron concentration was measured from the absorbance
of the Fe2+–Ferene S complex (ε593 = 34.5 mM–1 cm–1),[88] normalized by the viable cell counts and reported
as Fe atoms per cell.
Statistical Analysis
Statistical
significance between
the means and standard deviation of values obtained in experiments
comparing results from untreated vs treated with antibiotic or analogue
conditions was determined using one-way ANOVA followed by Tukey’s
multiple post hoc test, with the aid of SigmaPlot (Systat Software,
Inc. CA).
X-ray Crystallography
Crystallization
screening of
wild type BfrB was conducted in Compact 300 (Rigaku Reagents) sitting
drop vapor diffusion plates at 20 °C using equal volumes of protein
and crystallization solution equilibrated against 75 μL of the
latter. Crystals displaying a prismatic morphology were obtained in
1–2 days from the Cryo 1–2 HT screen (Rigaku Reagents)
condition H6 (30% (v/v) PEG 200, 100 mM Na acetate pH 4.5, 100 mM
NaCl). To prepare the ligand complexes, stock solutions (100 mM) of
ligand in DMSO were mixed with the crystallization solution to obtain
a 10 mM ligand soaking solution. Crystals were transferred to the
soaking solution and incubated for 3 h before harvesting directly
from the drop and storing in liquid nitrogen. Due to the low solubility
of KM-5-66, a multicomponent mixture[89] composed of 25% (v/v) dioxane, 25% (v/v) glycerol, 25%
(v/v) diethylene glycol and 25% (v/v) ethylene glycol (SM3) was prepared
to improve the ligand solubility. The ligand stock solution (100 mM
in DMSO) was mixed in a 1:1 (v/v) ratio with SM3; 4 μL of the
resultant solution was mixed with 5uL of 2× crystallant solution
and 1 μL of 10× buffer (1 M HEPES pH 7.5) to give a 20
mM ligand solution. Crystals were transferred to the soaking solution
and incubated for 3 h before harvesting directly from the drop and
storing in liquid nitrogen. Data were collected at the Advanced Photon
Source beamline IMCA-CAT beamline 17-ID. Intensities were integrated
using XDS[90] via Autoproc[91] and the Laue class analysis and data scaling were performed
with Aimless.[92] Structure solution was
conducted by molecular replacement using the previously determined
structure of wt holo-BfrB (PDB: 5D8O)[33] as the
search model with Phaser.[93] Structure refinement
and manual model building were conducted with Phenix[94] and Coot,[95] respectively. Structure
validation was conducted with Molprobity.[96]
Authors: Janus A J Haagensen; Mikkel Klausen; Robert K Ernst; Samuel I Miller; Anders Folkesson; Tim Tolker-Nielsen; Søren Molin Journal: J Bacteriol Date: 2006-10-13 Impact factor: 3.490
Authors: Kate Eshelman; Huili Yao; Achala N D Punchi Hewage; Jacqueline J Deay; Josephine R Chandler; Mario Rivera Journal: Metallomics Date: 2017-06-21 Impact factor: 4.526
Authors: Camila Pimentel; Casin Le; Marisel R Tuttobene; Tomas Subils; Jasmine Martinez; Rodrigo Sieira; Krisztina M Papp-Wallace; Niroshika Keppetipola; Robert A Bonomo; Luis A Actis; Marcelo E Tolmasky; Maria Soledad Ramirez Journal: Pathogens Date: 2021-04-13
Authors: Huili Yao; Anabel Soldano; Leo Fontenot; Fabrizio Donnarumma; Scott Lovell; Josephine R Chandler; Mario Rivera Journal: Biomolecules Date: 2022-02-25